

Inventor: Yashwant M. Deo, et al.

Atty Docket No.: MXI-166

Application No.: 09/851614

Filing Date: May 8, 2001

Title: HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS

Documents Filed:

Transmittal Letter (1 page)

Preliminary Amendment In Response to Notice to Comply with Requirements for Nucleotide or Amino Acid Sequence Disclosure (3 pages)

Substitute Figure 13 (1 page)

Copy of Formalities Letter (1 page)

Associate Power of Attorney (1 page)

Acknowledgment postcard

Via: Express Mail: Airbill No. EV 354 228 219 US

Sender's Initials: JER/DLH/tjs

Date: July 2, 2003

Best Available Copy

Inventor: Yashwant M. Deo, et al.

Atty Docket No.: MXI-166

Application No.: 09/851614

Filing Date: May 8, 2001

Title: HUMAN MONOCLONAL ANTIBODIES TO DENDRITIC CELLS

Documents Filed:

Transmittal Letter (1 page)

Preliminary Amendment In Response to Notice to Comply with Requirements for Nucleotide or Amino Acid Sequence Disclosure (3 pages)

Substitute Figure 13 (1 page)

Copy of Formalities Letter (1 page)

Associate Power of Attorney (1 page)

Acknowledgment postcard

Via: Express Mail: Airbill No. EV 354 228 219 US

Sender's Initials: JER/DLH/tjs

Date: July 2, 2003



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/851614
		Filing Date	May 8, 2001
		First Named Inventor	Yashwant M. Deo
		Art Unit	1644
		Examiner Name	Ewoldt, Gerald R.
Total Number of Pages in This Submission	5	Attorney Docket Number	MXI-166

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Copy of Formality Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	Preliminary Amendment in Response to Notice to Comply with Requirements for Nucleotide or Amino Acid Sequence Disclosure: Substitute Figure 13; Associate Power of Attorney; Acknowledgment postcard.	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Remarks	
<input type="checkbox"/> Certified Copy of Priority Document(s)			
<input type="checkbox"/> Response to Missing Parts/Incomplete Application			
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or individual name	LAHIVE & COCKFIELD, LLP Danielle L. Heritz - 43,670
Signature	
Date	July 2, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 364 228 219 U.S. in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 2, 2003

Signature: 

(Danielle L. Heritz)

Best Available Copy

Applicant No.: 09/155,644

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".* *I f necessary*
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY